ArticleOncotarget2017

Identification of MALT1 as both a prognostic factor and a potential therapeutic target of regorafenib in cholangiocarcinoma patients.

Chun-Nan Yeh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.